ADC Therapeutics (ADCT) Q2 2026 earnings review
Major FDA Setback Threatens Growth Narrative as Base Business Flatlines
ADC Therapeutics reported Q2 2026 net product revenues of $18.6M, a stable but stagnant result that was entirely overshadowed by a severe regulatory blow. The FDA raised 'substantial concerns' regarding Grade 5 (fatal) events and marginal treatment benefits in the critical LOTIS-5 trial. This trial was previously management's primary catalyst for unlocking $200M-$300M in new peak sales and driving 2027 revenue growth. To survive the delay, the company executed a 17% workforce reduction, slashing R&D expenses by 42% YoY and extending its cash runway to 2028. With its near-term catalyst severely impaired, the investment thesis now pivots heavily to earlier-stage combinations (LOTIS-7) and cost control.
🐂 Bull Case
Aggressive cost cuts (R&D down to $17.4M, 17% workforce reduction) and a $219.1M cash balance ensure survival through 2028, removing near-term dilution risk.
Enrollment of 100 patients for the LOTIS-7 trial (ZYNLONTA + glofitamab) is complete. The company plans to submit for Breakthrough Therapy Designation this year, potentially bypassing the LOTIS-5 roadblock.
🐻 Bear Case
The FDA's concern over fatal (Grade 5) events and marginal efficacy in LOTIS-5 severely jeopardizes the sBLA for 2nd-line DLBCL. Without this, the projected 2027 revenue inflection is dead in the water.
Despite management citing 'commercial momentum,' Q2 product revenue fell sequentially to $18.6M from $20.0M in Q1. The base 3L+ indication is not growing.
⚖️ Verdict: 🔴
Bearish. The company's entire 2026-2027 bull thesis hinged on LOTIS-5 success. The FDA's severe safety and efficacy concerns fundamentally break the near-term growth narrative, leaving investors holding a stagnant commercial asset while waiting for LOTIS-7 data to mature.
Key Themes
LOTIS-5 Regulatory Path Reversing
The FDA pre-sBLA meeting yielded a worst-case scenario: the agency noted 'substantial concerns regarding the benefit-risk... based on the imbalance in Grade 5 events, when assessed in the context of a marginal treatment benefit.' Management is now 'assessing the best regulatory path forward.' This effectively kills the near-term timeline for a 2L+ approval and jeopardizes the $200M-$300M peak revenue opportunity previously modeled for this combination.
Contradictory 'Commercial Momentum'
CEO Ameet Mallik cited 'continued commercial momentum,' but the data directly contradicts this. Q2 2026 net product revenue of $18.6M was essentially flat YoY ($18.1M) and actually declined sequentially from Q1 2026 ($20.0M) and Q4 2025 ($22.3M). The 3L+ DLBCL market for ZYNLONTA remains firmly stable, meaning the company continues to burn cash without a growing top line.
Aggressive Cost Control Decelerating Cash Burn
To offset revenue stagnation and regulatory delays, ADCT is aggressively cutting costs. A 17% workforce reduction will yield $10M in annualized savings. R&D expenses plummeted 42% YoY to $17.4M, driven by the completion of LOTIS-5/7 enrollment and discontinued programs. Total adjusted operating expenses dropped 22% YoY, ensuring the $219.1M cash pile lasts into 2028.
LOTIS-7 Combination Pivot
With LOTIS-5 faltering, LOTIS-7 (ZYNLONTA + glofitamab) becomes the critical pipeline asset. The 100-patient enrollment is complete, and ADCT claims the safety profile remains consistent with prior disclosures (avoiding the fatal event imbalances seen in LOTIS-5). The company plans to submit this data for Breakthrough Therapy Designation (BTD) later this year.
Macro Regulatory Stringency on Accelerated Approvals
The FDA's harsh stance on LOTIS-5 reflects a broader macro theme: the agency is increasingly intolerant of marginal benefit profiles accompanied by toxicity in the oncology space, particularly for confirmatory trials of accelerated approvals. This heightened regulatory hurdle raises the risk premium for ADCT's remaining pipeline.
Gross Margin Pressure from Personnel Reallocation
Cost of product sales jumped nearly 3x YoY, from $0.8M to $2.3M. This was driven by a $1.1M reallocation of personnel costs from R&D to commercial manufacturing. As the company winds down clinical supply activities and shifts staff to the commercial side, this structural margin compression will persist.
Indolent Lymphoma Expansion Advancing
Beyond DLBCL, the Marginal Zone Lymphoma (MZL) investigator-initiated trial continues to mature. Data has been submitted to ASH, and management intends to seek a BTD for MZL. This represents a potential $100M-$200M opportunity in a setting with lower competitive intensity.
Other KPIs
Decelerating sharply. Down 42% YoY from $30.1M in 25Q2. This drop reflects the conclusion of massive trial enrollments (LOTIS-5 and 7) and a deliberate strategic shift to slash burn rate, sacrificing future early-stage pipeline development for corporate survival.
Improving significantly from an adjusted net loss of $28.7M a year ago. The improvement is entirely driven by Opex reductions rather than top-line growth, highlighting management's success in right-sizing the business to match the current stagnant revenue reality.
Guidance
Accelerating cost discipline. The 17% global workforce reduction announced in Q2 will generate an estimated $10M in annual savings, effectively buying the company more time to navigate the LOTIS-5 FDA fallout.
Stable. The company maintained its guidance that the $219.1M in cash will last into 2028. However, with the LOTIS-5 approval timeline likely pushed back (or canceled entirely), this cash runway must now stretch to cover LOTIS-7 readouts and potential regulatory submissions.
Key Questions
LOTIS-5 Next Steps
Given the FDA's 'substantial concerns' over Grade 5 events and marginal benefit in LOTIS-5, is the company considering abandoning the sBLA entirely, or is there a path to salvage the data through subset analyses?
LOTIS-7 Read-Across
How does the FDA's strict stance on the LOTIS-5 benefit-risk profile change your confidence in LOTIS-7's regulatory path, particularly regarding the bar for safety in 2L+ DLBCL?
Revenue Inflection Delay
Previously, management guided to revenue growth accelerating in 2027 based on LOTIS-5. With that trial now facing severe regulatory hurdles, should investors assume the 2027 inflection point is delayed until LOTIS-7 is approved?